Lipoprotein lipase and triglyceride-rich lipoprotein metabolism

Nutrition in Clinical Practice

Volumn 16, Issue 5, 2001, Pages 273-279

  Miles, John M ^a   Park, Yongsoon ^a   Harris, William S ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0344858071     PISSN: 08845336     EISSN: None     Source Type: Journal    
DOI: 10.1177/088453360101600502     Document Type: Review

References (96)

1. Rodbell M. Metabolism of isolated fat cells. Effects of hormones on glucose metabolism and lipolysis. J Biol Chem 239:375-380, 1964.
2. Cherkes A, Gordon R Jr. The liberation of lipoprotein lipase by heparin from adipose tissue incubated in vitro. J Lipid Res 1:97-101, 1959.
3. Korn E. Clearing factor, a heparin-activated lipoprotein lipase. I. Isolation and characterization of the enzyme from normal rat heart. J Biol Chem 215:1-14, 1955.
4. van der Vusse G, Glatz J, Stam H, et al. Fatty acid homeostasis in the normoxic and ischemic heart. Physiol Rev 72:881-940, 1992.
5. Hamsten A. Hypertriglyceridaemia, triglyceride-rich lipoproteins and coronary heart disease. Bailliere Clin Endo Metab 4:895-922, 1990.
6. Havel R. Postprandial hyperlipidemia and remnant lipoproteins. Curr Opin Lipidol 5:102-109, 1994.
7. Benlian P, DeGennes J, Foubert L, et al. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med 335:848-854, 1996.
8. Brunzell JD. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. IN The Metabolic and Molecular Bases of Inherited Disease, Vol II. Scrover CR, Beaudet AL, Sly WS, et al (eds). McGraw-Hill, Inc. New York, 1995, pp 1913-1932.
9. Jensen D, Schlaepfer I, Morin C, et al. Prevention of diet-induced obesity in transgenic mice overexpressing skeletal muscle lipoprotein lipase. Am J Physiol 273:R683-R689, 1997.
10. Yost T, Jensen D, Eckel R. Weight regain following sustained weight reduction is predicted by relative insulin sensitivity. Obes Res 3:583-587, 1995.
11. Ferreira LDMC-B, Pulawa LK, Jensen DR, et al. Overexpressing human lipoprotein lipase in mouse skeletal muscle is associated with insulin resistance. Diabetes 50:1064-1068, 2001.
12. Boden G, Lebid B, Schatz M, et al. Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 50:1612-1617, 2001.
13. Kraemer F. Role of lipoprotein lipase and apolipoprotein E secretion by macrophages in modulating lipoprotein uptake: Possible role in acceleration of atherosclerosis in diabetes. Diabetes 41:77-80, 1992.
14. Goldberg I. Lipoprotein lipase and lipolysis: Central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 37:693-707, 1996.
15. Havel R, Gordon R Jr. Idiopathic hyperlipemia: Metabolic studies in an affected family. J Clin Invest 39:1777-1790, 1960.
16. Eckel RH. Lipoprotein lipase: A multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 320:1060-1068, 1989.
17. Ginsberg H. Changes in lipoprotein kinetics during therapy with fenofibrate and other fibric acid derivatives Am J Med 83:66-70, 1987.
18. Kantor M, Cullinane E, Sady S, et al. Exercise acutely increases high density lipoprotein-cholesterol and lipoprotein lipase activity in trained and untrained men. Metabolism 36:188-192, 1987.
19. Bagdade J, Porte D Jr, Bierman E. Diabetic lipemia. A form of acquired fat-induced lipemia. N Engl J Med 276:427-433, 1967.
20. Goldberg D, Rumsey W, Kendrick Z. Exercise activation of myocardial lipoprotein lipase in male and estrogen-treated female rats. Metabolism 33:964-969, 1984.
21. Rogers M, Robinson D. Effects of cold exposure on heart clearing factor lipase and triglyceride utilization in the rat. J Lipid Res 15:263-272, 1974.
22. Kiens B, Lithell H, Mikines KJ, et al. Effects of insulin and exercise on muscle lipoprotein lipase activity in man and its relation to insulin action. J Clin Invest 84:1124-1129, 1989.
23. Obregon M, Cannon B, Nedergaard J. Postnatal selective suppression of lipoprotein lipase gene expression in brown adipose tissue (relative to the expression of the gene for the uncoupling protein) is not due to adrenergic insensitivity: A possible specific inhibitory effect of colostrum. Biochem J 314:261-267, 1996.
24. Asayama K, Amemiya S, Kusano S, et al. Growth-hormone-induced changes in postheparin plasma lipoprotein lipase and hepatic triglyceride lipase activities. Metabolism 33:129-131, 1984.
25. Karpe F, Olivecrona T, Walldius G, et al. Lipoprotein lipase in plasma after an oral fat load: Relation to free fatty acids. J Lipid Res. 33:975-984, 1992.
26. Peterson J, Bihain B, Bengtsson-Olivecrona G, et al. Fatty acid control of lipoprotein lipase: A link between energy metabolism and lipid transport. Proc Natl Acad Sci USA 87:909-913, 1990.
27. Coppack S, Yost T, Fisher R, et al. Periprandial systemic and regional lipase activity in normal humans. Am J Physiol 270: E718-E722, 1996.
28. Krauss R, Levy R, Fredrickson D. Selective measurement of two lipase activities in postheparin plasma from normal subjects and patients with hyperlipoproteinemia. J Clin Invest 54:1107-1124, 1974.
29. Lithell H, Hellsing K, Lundqvist G, et al. Lipoprotein-lipase activity of human skeletal muscle and adipose tissue after intensive physical exercise. Acta Physiol Scand 105:312-315, 1979.
30. Iverius P, Brunzell J. Human adipose tissue lipoprotein lipase: Changes with feeding and relation to postheparin plasma enzyme. Am J Physiol 249:E107-E114, 1985.
31. Vilella E, Joven J, Fernandez M, et al. Lipoprotein lipase in human plasma is mainly inactive and associated with cholesterol-rich lipoproteins. J Lipid Res 34:1555-1564, 1993.
32. Tornvall P, Olivecrona G, Karpe F, et al. Lipoprotein lipase mass and activity in plasma and their increase after heparin are separate parameters with different relations to plasma lipoproteins. Arterioscler Thromb Vasc Biol 15:1086-1093, 1995.
33. Berr F, Eckel R, Kern FJ. Plasma decay of chylomicron remnants is not affected by heparin-stimulated plasma lipolytic activity in normal fasting man. J Lipid Res 26:852-859, 1985.
34. Kern P, Martin R, Carty J, et al. Identification of lipoprotein lipase immunoreactive protein in pre- and postheparin plasma from normal subjects and patients with type I hyperlipoproteinemia. J Lipid Res 31:17-26, 1990.
35. Zambon A, Schmidt I, Beisiegel U, et al. Dimeric lipoprotein lipase is bound to triglyceride-rich plasma lipoproteins. J Lipid Res 37:2394-2404, 1996.
36. Applebaum D, Goldberg A, Pykalisto O, et al. Effect of estrogen on post-heparin lipolytic activity. Selective decline in hepatic triglyceride lipase. J Clin Invest 59:601-608, 1977.
37. Reitman J, Kosmakos F, Howard B, et al. Characterization of lipase activities in obese Pima Indians. Decreases with weight reduction. J Clin Invest 70:791-797, 1982.
38. Olivecrona T, Bengtsson-Olivecrona G. Lipoprotein lipase and hepatic lipase. Curr Opin Lipidol 4:187-196, 1993.
39. Enerback S, Gimble J. Lipoprotein lipase gene expression: Physiological regulators at the transcriptional and post-transcriptional level. Biochim Biophys Acta 1169:107-125, 1993.
40. Eckel R, Goldberg I, Steiner L, et al. Plasma lipolytic activity. Relationship to postheparin lipolytic activity and evidence for metabolic regulation. Diabetes 37:610-615, 1988.
41. Glaser D, Yost T, Eckel R. Preheparin lipoprotein lipolytic activities: Relationship to plasma lipoproteins and postheparin lipolytic activities. J Lipid Res 33:209-214, 1992.
42. Harris W, Lu G, Rambjor G, et al. Influence of n-3 fatty acid supplementation on the endogenous activities of plasma lipases. Am J Clin Nutr 66:254-260, 1997.
43. Boberg J. Quantitative determination of heparin released lipoprotein lipase activity in human plasma. Lipids 5:452-456, 1970.
44. Nilsson-Ehle P, Garfinkel A, Schotz M. Positional specificity of adipose tissue lipoprotein lipase. Lipids 9:548-553, 1974.
45. Twu J, Nilsson-Ehle P, Schotz M. Hydrolysis of tri- and mono-acylglycerol by lipoprotein lipase: Evidence for a common active site. Biochemistry 15:1904-1976, 1909.
46. Olivecrona T. Metabolism of chylomicrons labeled-with C14-glyceroI-H3-palmitic acid in the rat. J Lipid Res 3:439-444, 1962.
47. Fielding B, Humphreys S, Shadid S, et al. Plasma mono-, di- and triacylglycerol measurements in a study of fat uptake by human adipose tissue in vivo. Biochem Soc Trans 23(Suppl):487S, 1995.
48. Oscai LB, Essig DA, Palmer WK. Lipase regulation of muscle triglyceride hydrolysis. J Appl Physiol 69:1571-1577, 1990.
49. 14C-labelled substrates in humans. J. Clin. Invest. 79:359-366, 1987.
50. Wolfe RR, Shaw JHF, Durkot MJ. Effects of sepsis on VLDL kinetics: Responses in basal state and during glucose infusion. Am. J Physiol. 248:E732-E740, 1985.
51. Coppack SW, Judd RL, Miles JM. Uptake and release of glycerol and free fatty acids by human adipose and muscle tissues in vivo. Am J Physiol 276:E233-E240, 1999.
52. Wolfe RR, Peters EJ. Lipolytic response to glucose infusion in human subjects. Am. J Physiol 252:E218-E223, 1987.
53. Vaughan M. The production and release of glycerol by adipose tissue incubated in vitro. J Biol Chem 237:3354-3358, 1962.
54. Edens NK, Leibel RL, Hirsch J. Mechanism of free fatty acid re-esterification in human adipocytes in vitro. J Lipid Res 31:1423-1431, 1990.
55. Jensen MD. Regulation of forearm lipolysis in different types of obesity. In vivo evidence for adipocyte heterogeneity. J Clin Invest 87:187-193, 1991.
56. Wicklmayr M, Dietze G, Rett K, et al. Evidence for a substrate regulation of triglyceride lipolysis in human skeletal muscle. Horm Metab Res 17:471-475, 1985.
57. Levy R, Glueck C. Hypertriglyceridemia, diabetes mellitus, and coronary vessel disease. Arch Intern Med 123:220-228, 1969.
58. Semenkovich C, Heinecke J. The mystery of diabetes and atherosclerosis: Time for a new plot. Diabetes 46:327-334, 1997.
59. Nikkila E, Kekki M. Plasma triglyceride transport kinetics in diabetes mellitus. Metabolism 22:1-22, 1973.
60. Kissebah AH, Alfarsi S, Evans DJ, et al. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus. Diabetes 31:217-225, 1982.
61. Lewis B, Mancini M, Mattock M, et al. Plasma triglyceride and fatty acid metabolism in diabetes mellitus. Eur J Clin Invest 2:445-453, 1972.
62. Brunzell J, Porte DJ, Bierman E. Abnormal lipoprotein-lipase-mediated plasma triglyceride removal in untreated diabetes mellitus associated with hypertriglyceridemia. Metabolism 28:901-907, 1979.
63. Reaven G, Hill D, Gross R, et al. Kinetics of triglyceride turnover of very-low-density lipoproteins in human plasma. J Clin Invest 44:1826-1833, 1965.
64. Brunzell JD, Hazzard WR, Porte D Jr, et al. Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. J Clin Invest 52:1578-1585, 1973.
65. Seidner DL, Mascioli EA, Istfan NW, et al. Effects of long-chain triglyceride emulsions on reticuloendothelial system function in humans. JPEN 13:614-619, 1989.
66. Lindh A, Rossner S. Immediate Intralipid clearance from plasma in critically ill patients after a single-dose injection. Crit Care Med 15:826-830, 1987.
67. Jensen GL, Mascioli EA, Seidner DL, et al. Parenteral infusion of long- and medium-chain triglycerides and reticuloendothelial system function in man. JPEN 14:467-471, 1990.
68. Karpe F, Humphreys S, Samra J, et al. Clearance of lipoprotein remnant particles in adipose tissue and muscle in humans. J Lipid Res 38:2335-2343, 1997.
69. Nestel P, Denborough M, O'Dea J. Disposal of human chylomicrons administered intravenously in ischaemic heart disease and essential hyperlipemia. Circ Res 10:786-791, 1962.
70. Boberg J, Carlson LA, Hallberg D. Application of a new intravenous fat tolerance test in the study of hypertriglyceridemia in man. J Atheroscler Res 9:159-169, 1969.
71. Redgrave T, Ly H, Quintao E, et al. Clearance from plasma of triacylglycerol and cholesteryl ester after intravenous injection of chylomicron-like lipid emulsions in rats and man. Biochem J 290:843-847, 1993.
72. Nakandakare E, Lottenberg S, Oliveira H, et al. Simultaneous measurements of chylomicron lipolysis and remnant removal using a doubly labeled artificial lipid emulsion: Studies in normolipidemic and hyperlipidemic subjects. J Lipid Res 35:143-152, 1994.
73. Iriyama K, Nishiwaki H, Terashima H, et al. Apolipoprotein C-II modifications associated with an infusion of artificial lipid particles. JPEN 12:60-62, 1988.
74. Grundy S, Mok H. Chylomicron clearance in normal and hyper-lipidemic man. Metabolism 25:1225-1239, 1976.
75. Park Y, Grellner WJ, Harris WS, et al. A new method for the study of chylomicron kinetics in vivo. Am J Physiol 279:E1258-1263, 2000.
76. Bjorkegren J, Packard C, Hamsten A, et al. Accumulation of large very low density lipoprotein in plasma during intravenous infusion of a chylomicron-like triglyceride emulsion reflects competition for a common lipolytic pathway. J Lipid Res 37:76-86, 1996.
77. Karpe F, Hultin M. Endogenous triglyceride-rich lipoproteins accumulate in rat plasma when competing with a chylomicron-like triglyceride emulsion for a common lipolytic pathway. J Lipid Res 36:1557-1566, 1995.
78. Potts JL, Fisher RM, Humphreys SM, et al. Peripheral triacyl-glycerol extraction in the fasting and post-prandial states. Clin Sci 81:621-626, 1991.
79. Cohn J, Johnson E, Millar J, et al. Contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters. J Lipid Res 34:2033-2040, 1993.
80. Schneeman B, Kotite L, Todd K, et al. Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans. Proc Natl Acad Sci USA 90:2069-2073, 1993.
81. Miles JM. Intravenous fat emulsions in nutritional support. Curr Op Gastroenterol 7:306-311, 1991.
82. Driscoll DF. Physicochemical assessment of total nutrient admixture safety and stability: Quantifying the risk. Nutrition 13:166-167, 1997.
83. Kelbel I, Koch T, Weber A, et al. Alterations of bacterial clearance induced by propofol. Acta Anesthesiol Scand 43:71-76, 1999.
84. Robin AP, Arain I, Phuangsab A, et al. Intravenous fat emulsion acutely suppresses neutrophil chemiluminescence. JPEN 13:608-613, 1989.
85. Freeman J, Goldmann DA, Smith NE, et al. Association of intravenous lipid emulsion and coagulase-negative staphylococcal bacteremia in neonatal intensive care units. N Engl J Med 323:301-308, 1990.
86. Avila-Figueroa C, Goldmann DA, Richardson DK et al. Intravenous lipid emulsions are the major determinant of coagulase-negative staphylococcal bacteremia in very low birth weight newborns. J Pediatr Infect Dis J 17:10-17, 1998.
87. Batistella FD, Widergren JT, Anderson JT, et al. A prospective, randomized trial of intravenous fat emulsion administration in trauma victims requiring TPN. J Trauma 43:52-58, 1997.
88. Herson VC, Block C, Eisenfeld L, et al. Effect of intravenous fat infusion on neonatal neutrophil and platelet function. JPEN 13:620-622, 1989.
89. Park W, Paust H, Schroder H. Lipid infusion in premature infants suffering from sepsis. JPEN 8:290-292, 1984.
90. Hammerman C, Aramburo MJ, Hill V. Intravenous lipids in newborn lungs: Thromboxane-mediated effects. Crit Care Med 17:430-436, 1989.
91. McKeen CR, Brigham KC, Bowers RE, et al. Pulmonary vascular effects of fat emulsion infusion in unanesthetized sheep. J Clin Invest 61:1291-1297, 1978.
92. Venus B, Smith RA, Patel. C, et al. Hemodynamic and gas exchange alterations during Intralipid infusion in patients with adult respiratory distress syndrome. Chest 95:1278-1281, 1989.
93. Hwang T-L, Huanng S-L, Chen M-F. Effects of intravenous fat emulsion on respiratory failure. Chest 97:935-938, 1990.
94. Kollef MH, McCormack MT, Caras WE, et al. The fat overload syndrome: Successful treatment with plasma exchange. Ann Intern Med 112:545-546, 1990.
95. Miles JM. Energy requirements in nutrition support: Quantitative and qualitative considerations. Frontiers Clin Nutr 3:9-12, 1994.
96. McMahon M, Miles JM. Common errors in parenteral and enteral nutrition. Sem Gastrointest Dis 4:127-136, 1993.